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DMARD AUROTHIOMALATE INHIBITS COX-2, IL-6 AND
MMP-3 EXPRESSION IN CHONDROCYTES BY INCREASING
MKP-1 EXPRESSION AND DECREASINGP38
PHOSPHORYLATION
R. Nieminen1, R. Korhonen1, T. Moilanen2, A.R. Clark3,
E. Moilanen1
1Med. Sch., University of Tampere, Finland; 2Coxa Hosp. for Joint
Replacement, Tampere, Finland; 3The Kennedy Inst. of
Rheumatology Div., Imperial Coll., London, United Kingdom
Purpose: Aurothiomalate is a disease modifying antirheumatic
drug that suppresses inﬂammation and retards cartilage degrada-
tion and bone erosion in arthritis. The molecular mechanisms of
action of aurothiomalate are not known in detail. Mitogen-activated
protein kinase (MAPK) pathways are major signaling pathways in
inﬂammation, which regulate the production of many factors known
to mediate inﬂammation and cartilage destruction in OA and RA.
In the present study we investigated the effects of aurothiomalate
on the activity of p38 MAPK and expression of MAPK phosphatase
1 (MKP-1), COX-2, MMP-3 and IL-6 in chondrocytes and intact
cartilage.
Methods: Cartilage tissue was obtained from the leftover pieces
of total knee replacement surgery from patients with OA and RA
and from MKP-1-/- and wild type mice. Immortalized H4 murine
chondrocytes* were used in cell culture experiments.
Results: Aurothiomalate inhibited IL-1β -induced COX-2 expres-
sion and prostaglandin E2 (PGE2) production by destabilizing
COX-2 mRNA, as did the p38 MAPK inhibitor SB203580. Inter-
estingly, aurothiomalate also increased the expression of MKP-1
and reduced IL-1β -induced phosphorylation of p38 MAPK. Knock-
down of MKP-1 by siRNA signiﬁcantly impaired the ability of au-
rothiomalate to inhibit the phosphorylation of p38 MAPK and the
expression of COX-2, MMP-3 and IL-6. Likewise, aurothiomalate
reduced COX-2, MMP-3 and IL-6 expression in human rheuma-
toid arthritis (RA) and osteoarthritis (OA) cartilage, and in articular
cartilage from wild type mice but not in cartilage from MKP-1-/-
mice.
Conclusions: The results provide a novel mechanism for the anti-
inﬂammatory and anti-erosive action of aurothiomalate through
increased MKP-1 expression, reduced p38 MAPK activation and
suppressed expression of COX-2, MMP-3 and IL-6. MKP-1 may
therefore be a promising novel target for the development of
disease modifying drugs for RA and OA.
*Murine H4 chondrocyte cell line was kindly provided by Peter van
der Kraan, Laboratory of Experimental Rheumatology, University
Medical Center Nijmegen, Netherlands.
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COLLAGEN PEPTIDE SUPPLEMENTATION STIMULATES
PROTEOGLYCAN BIOSYNTHESIS AND AGGRECAN
EXPRESSION OF ARTICULAR CHONDROCYTES
M. Schunck1, C.H. Schulze2, S. Oesser1
1Collagen Res. Inst., Kiel, Germany; 2Dept. of Gen. Surgery and
Traumatology, Klinikum Elmshorn, Elmshorn, Germany
Purpose: Over the past years hydrolyzed collagen has been used
in the treatment of OA and positive effects on joint health were
demonstrated in pre-clinical experiments and clinical studies. The
therapeutic mechanism, however, is still unknown.
The aim of this study was to investigate the inﬂuence of a
speciﬁc Collagen Hydrolysate (FORTIGEL®) on the proteoglycan
metabolism of the extracellular matrix (ECM) of chondrocytes.
Methods: Primary articular chondrocytes were isolated of porcine
ankle joint cartilage and cultured under reduced oxygen con-
ditions. The culture medium was supplemented with 0.5 mg
FORTIGEL®/ml according to recommended daily dose of pa-
tients. At different time points of the culture period the amount
of secreted and cell-associated proteoglycans (PGs) were quanti-
ﬁed by measuring 35S-sulphate incorporation. Total proteoglycan
biosynthesis was measured by speciﬁc staining of sulphate groups
with Alcian blue. Moreover, the expression of aggrecan was deter-
mined by Northern Blot analysis and the amount of aggrecan in
the ECM was analyzed via Western Blotting.
Results: Supplementation of the culture medium with FORTIGEL®
resulted in a statistically signiﬁcant (p<0.05) increase of total PG
synthesis. The amount of secreted and cell-associated PGs was
signiﬁcantly increased up to 1.6-fold after FORTIGEL® treatment
compared with the control cells. In particular, administration of
FORTIGEL® was associated with a statistically signiﬁcant increase
(p<0.05) of aggrecan biosynthesis shown by RNA expression and
accumulation of aggrecan intermediates and of native aggrecan in
the ECM as well.
Conclusions: These results indicate a stimulatory effect of
FORTIGEL® on the metabolism of proteoglycans in chondrocytes.
Thus FORTIGEL® may be helpful reducing degenerative changes
of the ECM by stimulating anabolic processes in cartilage tissue.
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THE EFFECTS OF DEOXYNIVALENOL, NIVALENOL, T-2
TOXIN AND SELENIUM SUPPLEMENTATION ON IN VITRO
TISSUE ENGINEERED CARTILAGE METABOLISM
J. Cao1, M. Lu1, F. Liu1, Q. Fu1, J. Liu1, S. Li1, J. Chen1,
A. Zhang1, Z. Zhang1, J. Zhu1, C.E. Hughes2, B. Caterson2
1Xi’an Jiaotong Univ., Xi’an, China; 2Cardiff Univ., Cardiff, United
Kingdom
Purpose: To investigate the effects of Nivalenol (NIV), Deoxyni-
valenol (DON) and T-2 toxin, in the presence and absence of
Selenium (Se), on the metabolism of tissue engineered cartilage.
These in vitro cartilage cultures mimic those found in Kashin-
Beck Disease (KBD) environments that cause diarthrodial joint
degeneration in skeletal joint development and osteoarthritis with
ageing.
Methods: Bone matrix gelatin (BMG) was prepared from cancel-
lous bones of adult rabbits using previously published procedures
(Li et al. J Zhejiang Univ Sci B. 2008, 9(1): 22-33). Human chon-
drocytes were isolated from a 10th-week human embryo cartilage
anlagen by sequential enzyme treatments. One million Passage 2
cells were seeded onto BMG grafts for pre-culture for 48 hours.
Three toxins (DON, NIV & T-2 toxin), in the presence or absence
of Se, were added: DON, 1.0μg/ml; NIV, 0.1μg/ml; T-2, 0.01μg/ml;
Se, 0.1μg/ml. After 3 weeks culture in vitro, the BMG with the
tissue-engineered cartilage graft was ﬁxed, embedded, and cut
into 14μm slices for histological analysis. Slides were stained
with hematoxylin & eosin (H&E) and toluidine blue. Immunohisto-
chemical analysis was used to detect the expression of types II
& X collagen, aggrecan, MMP1, MMP3, TIMP1, TIMP3 and α2
macroglobulin.
Results: H&E staining showed that the tissue-engineered carti-
lage grafts were very similar to normal cartilage in vivo, with chon-
drocytes localised in lacunae, separated from each other by the
interterritorial extracellular matrix. There were no necrotic chon-
drocytes observed in the Control or the Toxin/Se treated groups.
Control tissue engineered cartilage grafts expressed aggrecan and
type II collagen, and a small amount of type X collagen. Immuno-
histochemical analysis of grafts exposed to DON, NIV and T-2
toxin showed decreased expression of type II collagen and aggre-
can. However, Se addition restored type II collagen and aggrecan
staining in the presence of these Toxins. There was increased
MMP-1 and MMP-3 expression in the Toxin-treated grafts. How-
S144 Poster Presentations
ever, Se addition reduced this expression. In contrast, exposure
to DON, NIV and T-2 toxin caused depressed TIMP-1 and TIMP-3
levels compared with the Control; this reduction was reversed
with Se addition. Se addition also reversed the expression. α2
macroglobulin that was lowered by the three Toxins.
Conclusions: This study indicates that three toxins (DON, NIV
and T-2 toxin) all depress type II collagen and aggrecan expres-
sion in tissue engineered cartilage grafts cultured in vitro. The
levels of MMP-1 and MMP-3 were increased but the levels of
TIMP-1, TIMP-3 and α2 macroglobulin were all decreased in the
presence of Toxins. Addition of Se reversed all of the expression
effects produced by these Toxins. These in vitro results provide
evidence for the potential biological mechanisms underlying carti-
lage degradation in the pathogenesis of KBD and how Selenium
addition reverses these pathological effects.
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REGULATION OF MICROSOMAL PROSTAGLANDIN E2
SYNTHASE-1 AND 5-LIPOXYGENASE-ACTIVATING
PROTEIN/5-LIPOXYGENASE BY 4-HYDROXYNONENAL IN
OSTEOARTHRITIC CHONDROCYTES
S.-H. Chen, Q. Shi, H. Fahmi, M. Benderdour
Univ. of Montreal, Montreal, QC, Canada
Purpose: Recently, we reported that the induction of
cyclooxygenase-2 (COX-2) decreased dramatically after 24 hrs
of incubation with 4-hydroxynonenal (4-HNE), a product of lipid
peroxidation. This study aimed to investigate whether HNE is re-
sponsible for the shunt from COX-2 to 5-lipoxygenase-activating
protein (FLAP)/5-lipoxygenase (5-LOX) in human osteoarthritic
(OA) chondrocytes.
Methods: OA chondrocytes were treated with 10 μM of 4-HNE
at different times of incubation (0 to 72 hrs). The protein level of
mPGES-1 was evaluated by Western blot and that of prostaglandin
E2 (PGE2) and leukotriene 4 (LTB4) was determined by EIA using
commercial kits. The level of mPGES-1 and FLAP/5-LOX mRNA
was measured by real-time RT-PCR.
Results: HNE induced the production of both PGE2 and LTB4 by
chondrocytes, but in opposite fashion. The level of PGE2 increased
during the short period of stimulation (0-24 hrs), whereas that of
LTB4 increased after a long period of stimulation (48 and 72
hrs), where the level of PGE2 decreased. The Western blot data
showed that protein expression of mPGES-1 increased gradually
in treated cells with 4-HNE, to reach a maximum level after 16
h of incubation. At mRNA level, 4-HNE induced mPGES-1 and
FLAP/5-LOX expression after 4 and 48 h of incubation respectively.
Conclusions: Our results showed the shunt from the COX-2 to
FLAP/5-LOX pathway in HNE-induced human OA chondrocytes.
The increase in LTB4 level may be due to the decrease in that
of PGE2. Further experiments are in progress in other to de-
termine the molecular mechanism underlying this switch in OA
chondrocytes.
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EFFECT OF THREE DIFFERENT CHONDROITIN SULFATES
IN HUMAN OSTEOARTHRITIS CARTILAGE
S. Kwan Tat1, J.-P. Pelletier1, F. Mineau1, N. Duval2,
J. Martel-Pelletier1
1Osteoarthritis Res. Ctr., Notre-Dame Hosp., Univ. of Montreal
Hosp. Res. Ctr. (CRCHUM), Montreal, QC, Canada; 2Duval
Clinique Orthopédique, Laval, QC, Canada
Purpose: During the osteoarthritis (OA) process, the altered
metabolism of the chondrocytes is responsible for the extensive
breakdown of the cartilage in which pro-inﬂammatory cytokines
and matrix metalloproteases (MMPs) are highly implicated. Previ-
ous studies have demonstrated that chondroitin sulfate (CS) exerts
a protective effect on the cartilage. However, due to differences
in CS in terms of origin, purity and the production/puriﬁcation
process, we compared the effects of three different types of CS
on human OA cartilage.
Methods: Three types of CS were tested: namely CS#1 (porcine,
purity: 90.4%), CS#2 (bovine, purity: 93.0%), and CS#3 (Bioibérica
S.A.; bovine, purity: 99.9%). Treatment with each CS at 200 and
1000 μg/ml were performed in human OA cartilage explants in the
presence/absence of IL-1β, and the protein modulations of factors,
including PGE2, IL-6, and MMP-1, were investigated by speciﬁc
ELISA. The CS effect on the expression of the pro-anabolic factor,
collagen type II, was also investigated on OA chondrocytes using
quantitative PCR.
Results: In the presence of IL-1β, CS#3 at 200 μg/ml, but not
at 1000 μg/ml, reduced the level of MMP-1, PGE2 and IL-6.
CS#2 followed the same trend as CS#3, however, at a much
higher concentration, 1000 μg/ml. On the other hand, CS#1 was
much less efﬁcient in reducing the same catabolic markers and
very surprisingly, in the absence of IL-1β, it increased the three
catabolic factors tested, PGE2, IL-6, and MMP-1. As expected
IL-1β inhibits the gene expression level of the collagen type II; only
CS#3 was able to limit this inhibition. CS#1, in the presence or
absence of IL-1β, further decreased collagen type II expression.
Conclusions: This study provides data on the effect of different
CS on the cartilage metabolism. In this context, CS prescribed
for alleviating OA symptoms should be taken with care as the
origin, purity and/or production/puriﬁcation of the CS compound
could orientate the current OA disease process toward increased
catabolic pathways.
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PATHOLOGY OF THE OUTERBRIDGE IV LESION;
THERAPEUTIC IMPLICATIONS
L.L. Johnson1, C. Verioti1, J. Gelber1, D. D’Lima1, M. Spector2
1Shiley Ctr. for Orthopedic Res. and Ed., La Jolla, CA; 2Woman’s
Brigham Hosp., Harvard Univ., Boston, MA
Purpose: The purpose of this study is to examine the gross and
microscopic characteristics of the Outerbridge IV lesion that may
serve as the foundation for cartilage repair.
Methods: Human osteochondral specimens having Outerbridge
IV lesions were harvested following total knee surgery. They were
subject to visual examination before and after Safranin O staining.
Correlative histology was examined.
Results: The stained gross specimens showed cartilaginous ag-
gregates on the surface as well as multiple small depressions.
The microscopy showed cartilaginous aggregates on the surface
